A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects

NCT01045369 | Completed Phase 4 DMC

• 1 other identifier: 101-001
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to see if using a combination of other drug classes, like the ones that Kaletra® and Intelence™ belong to, can still help reduce the amount of HIV in your blood. Using Kaletra® and Intelence™ without other drugs is not approved by the FDA and so their use in this study is experimental.

Conditions

HIV Infections

Keywords

HIV; Treatment Naive

Outcome Measures

Primary Outcomes (2)

• Proportion of patients with plasma HIV-1 RNA < 400 copies/mL at weeks 24 and 48

  At weeks 24 and 48

• Proportion of patients with plasma HIV-1 RNA < 75 copies/mL at weeks 24 and 48

  At weeks 24 and 48

Secondary Outcomes (2)

• Proportion of patients with plasma HIV-1 RNA < 400 copies/mL or < 75 copies/mL at each study visit

  At weeks 24 and 48

• Number of weeks until HIV RNA < 400 copies/mL and < 75 copies/mL, respectively

  At weeks 24 and 48

Study Arms (1)

Kaletra And Intelence

EXPERIMENTAL

This is a Phase IV, 48-week, open-label, pilot study in 30 ARV-naïve patients examining the safety, viral response, and tolerability of Kaletra® and Intelence™ tablets.

Drug: Kaletra and Intelence Tablets

Interventions

Kaletra and Intelence Tablets DRUG

Kaletra 400 mg twice a day and Intelence Tablets 200mg twice a day.

Kaletra And Intelence

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• HIV-1 RNA ≥ 5000 copies/mL by Roche Amplicor 1.5v Primer
• More than 18 years of age
• Provide written informed consent and willingness to participate in and comply
• Less than 7 days of prior ART with any licensed or investigational compound
• Does not currently have or has not been treated for an active opportunistic infection (OI) within 30 days of screening
• Vital signs, physical examination and laboratory results do not exhibit evidence of acute illness
• A female who is a non-childbearing potentiator or if in child-bearing potential, has a negative serum pregnancy test at screen and agrees to one of the following: complete abstinence from intercourse from 2 weeks prior to administration of the study drug, throughout the study, and for at least 2 weeks after completion or premature discontinuation from the study to account for elimination of the investigational drug. Should a patient decide to become sexually active during the course of the study, she must be counseled and be willing to use one of the birth control methods like double barrier method, intrauterine device, sterilization and any other methods.
• NOTE: Data are insufficient to exclude a clinically important interaction of LPV/r with drugs, such as hormonal contraceptives, that are highly metabolized by the cytochrome P450 enzyme system. As a result, hormonal contraception is not considered adequate.

You may not qualify if:

• Patient with active AIDS-defining opportunistic infection in the 30 days prior to baseline and that, in the opinion of the investigator, would preclude the patient from participating in the study (See Appendix C).
• Patient has a weighted genotypic score for etravirine ≥3 . (See Appendix D)
• Patient has \>3 mutations at 10, 20, 24, 32, 33, 36, 46, 47, 48, 50, 54, 73, 82, 84, or 90 in protease or ≥1 of the following mutations in protease (I47A/V, V32I, or L76V).
• History of active substance abuse.
• Pregnant at time of screening evaluation or breast-feeding.
• Patient, in the opinion of the investigator, is unlikely to be able to complete the 48-week dosing period and protocol evaluations and assessments or adhere to the study drug regimen.
• Serious medical condition, such as diabetes, congestive heart failure, cardiomyopathy or other cardiac dysfunction, which in the opinion of the investigator would compromise the safety of the patient
• Malabsorption syndrome or other gastrointestinal dysfunction, which may interfere with drug absorption or render the patient unable to take oral medication.
• Undergoing interferon therapy for HCV or anticipates undergoing therapy during the course of this trial
• HBV co-infection
• Laboratory results within 30 days prior to the first dose of study medication:
• Hemoglobin concentration \< 8.0 g/dL
• Absolute neutrophil count \< 750 cells/mm3
• Platelet count \<50,000 cells/ mm3
• Aminotransferase (AST, ALT) \>3 times ULN

Sponsors & Collaborators

• Therapeutic Concepts: lead
• Abbott: collaborator
• Tibotec, Inc: collaborator
• BluKyne: collaborator

Study Sites (1)

Therapeutic Concepts, PA

Houston, Texas, 77004, United States

Location

MeSH Terms

Conditions

HIV Infections

Interventions

lopinavir-ritonavir drug combination; etravirine

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Study Officials

• Joseph C. Gathe, Jr., MD

  Therapeutic Concepts

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: January 8, 2010
• First Posted: January 11, 2010
• Study Start: January 1, 2010
• Primary Completion: April 1, 2011
• Study Completion: June 1, 2011
• Last Updated: May 1, 2017

Record last verified: 2010-01

Locations

US (1)